Better Context Better Decisions

Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.

$599
Posted in: Glucose Monitoring, Insulin Delivery, Other Aug 27 | 2024FENIX Analysis: Pump/AID Promotional Materials Post-ADA 2024Purchase Blast
$599
Posted in: Glucose Monitoring, Other Aug 26 | 2024Dexcom launches Stelo OTC Glucose Biosensor in the USPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, SGLT2i Aug 21 | 2024Lexicon Zynquista Adcom; Sesame to Offer Compounded SemaglutidePurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other Aug 20 | 2024Tirzepatide Three-Year Positive Pre-Diabetes and Weight-Loss Results; Medtronic CY Q2 ’24 (FY Q1 ’25) Earnings Update; Tandem iOS app update; August 19-22 CHMP AgendaPurchase Blast
$599
Posted in: Glucose Monitoring, Other Aug 15 | 2024FENIX Analysis: CGM Promotional Materials Post-ADA 2024Purchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery Aug 12 | 2024Insulet, Senseonics, Arrowhead, Biocon, and Akero Q2 ’24 EarningsPurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, Glucagon, Other Aug 08 | 2024Altimmune, Scholar Rock, Xeris, and Viatris Q2 ’24 EarningsPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Other Aug 08 | 2024Lilly Raises FY Guidance by $3B; Lilly Q2 ’24 Earnings; Novo Q2 ’24 London EventPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring, Insulin Delivery Aug 07 | 2024Abbott/Medtronic Strategic Partnership; Simplera Updates; Madrigal and MannKind Q2 ’24 EarningsPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Other Aug 07 | 2024STEP HFpEF Withdrawn; QM GLP/GIP Withdrawn; Novo Q2 ’24 EarningsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other Aug 01 | 2024FENIX Analysis: GLP-1RA Promotional Materials Post-ADA 2024Purchase Blast
1 2 3 4 5 6 95

Get the Latest Analysis

Stay informed and aligned with frequent updates to keep a pulse on the industry.

If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.